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Objective Given that the literature data indicates that ascorbic acid may have an anxiolytic effect, we hypothesized that a single 
oral administration of ascorbic acid could acutely affect emotional states. Methods The effects of acid ascorbic supplementation 
on anxiety and other emotional states were evaluated by the State‑Trait Anxiety Inventory (STAI), and Visual Analogue Mood Scale 
(VAMS). Immediately before, and 2 hours after receiving a single ascorbic acid dose (1000 mg) or placebo, 142 graduate students 
were evaluated by the STAI and VAMS in a randomized, double‑blind, placebo‑controlled trial. Results No changes from basal levels 
were observed in the STAI state‑anxiety or VAMS scores. However, the ingestion of ascorbic acid by the 25% more anxious healthy 
subjects (women; 14 control and 23 ascorbic acid), as defined by the STAI trait‑anxiety scale, produced a significant reduction 
from baseline anxiety scores in the STAI state‑anxiety scale and VAMS anxiety subscale. The study evaluated a small sample with 
narrow sociodemographic characteristics, composed mainly of healthy young females (> 94%) enrolled in post‑graduation courses, 
without controlling diet, physical activity, and formal psychiatric diagnosis. Conclusions: Despite the sample size limitation, this 
study provides the first evidence of an acute anxiolytic effect of ascorbic acid. Broader population studies are required to evaluate 
the clinical relevance of presented data.
Key words: ascorbic acid, anxiety, trait anxiety, State‑trait Anxiety Inventory (STAI), Visual Analog Mood Scale (VAMS)
INTRODUCTION
Anxiety is characterized by apprehension, worry 
and tension that may be understood as a physiolog‑
ical, adaptive response to potential threats (Perusini 
and Fanselow 2015). However, persistent or exaggerat‑
ed anxiety is pathological and constitutes the hallmark 
of anxiety disorders, which are the most common psy‑
chiatric disorders, with a lifetime prevalence of almost 
30% (Greenberg et al. 1999, Kessler et al. 2005, Viana and 
Andrade 2012). Anxiety disorders are classified by the 
Diagnostic and Statistical Manual of Mental Disorders, 
fifth edition (DSM‑V) in separation anxiety disorder, 
selective mutism, specific phobia, social phobia, panic 
disorder, agoraphobia, and generalized anxiety disor‑
der (American Psychiatric Association 2013). These dis‑
orders are more frequent in women than in men (Asher 
et al. 2017, Li and Graham 2017), and are well known to 
impair quality of life and performance at work, being 
highly costly to society (Baxter et al. 2014). Clinically 
relevant anxiety is also present in a myriad of mental 
illnesses, particularly mood disorders. For example, co‑
morbidity between major depression and anxiety disor‑
ders occur in more than 50% of patients (Kessler et al. 
2003). Of note, anxiety disorders are also often associ‑
ated with hyperthyroidism and inflammatory diseases 
such as rheumatoid arthritis, irritable bowel syndrome, 
diabetes, and asthma (Culpepper 2009, Hajebrahimi et 
al. 2016). Anxiety can be studied within a state‑trait 
paradigm, in which trait anxiety represents a general‑
ized, enduring individual predisposition to experience 
anxiety, while state anxiety consists of acute, transito‑
ry emotion (Endler and Kocovski 2001).
Antidepressants (especially selective serotonin and 
norepinephrine reuptake inhibitors) are the first line 
treatment for several anxiety disorders (Baldwin et al. 
2014, Bandelow et al. 2015, Katzman et al. 2014). Al‑
though effective in many patients, these drugs are not 
free of side effects, which include mainly metabolic, 
sexual, and cognitive dysfunctions (Masand and Gup‑
ta 2002, Uzun et al. 2010). Antidepressants typically 
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take several weeks to produce a therapeutic response 
and less than two thirds of patients show significant 
improvement in symptoms (Bystritsky 2006). The sci‑
entific and pharmaceutical community (Farach et al. 
2012) has avidly sought alternative drug regimen and 
novel drugs, able to produce a faster therapeutic re‑
sponse without serious side effects in larger propor‑
tions of patients.
Along the years, several drugs were incorporated in 
the repertoire for anxiety disorders therapies. The use 
of benzodiazepines is growing in the anxiety therapy, 
however, tolerance and dependence frequently devel‑
op (Gravielle 2016), and their long‑term prescription is 
controversial and known to be problematic in specific 
populations, such as the elderly and individuals with 
a history of substance abuse (Cloos and Ferreira 2009, 
Dell’osso and Lader 2013, Starcevic 2014). Recently, the 
use of pregabalin was included in the guidelines for the 
treatment of generalized anxiety disorder as the first 
line treatment (Katzman et al. 2014), or an alternative 
first line treatment (Baldwin et al. 2014). Pregabalin is 
an anticonvulsant drug that binds to the a2d subunit of 
the voltage‑dependent calcium channel in central ner‑
vous system, decreasing the release of neurotransmit‑
ters, which includes glutamate (Martinotti et al. 2013). 
Pregabalin is also able to increase the activity of gluta‑
mate transporter type 3, thus clearing glutamate from 
the synaptic cleft (Ryu et al. 2012).
Ascorbic acid is known as vitamin C, a water‑soluble 
antioxidant vitamin, essential to human beings and to 
several other mammals. The anion form (ascorbate) is 
the active form of vitamin C, known to have free radi‑
cal scavenging activity, thus reacting with free radicals, 
such as protein thiyl radical, protecting biomolecules 
from oxidative damage (Nauser et al. 2015). Vitamin C 
also participates indirectly as an antioxidant by regen‑
erating vitamin E, contributing to antioxidant protec‑
tion against lipid peroxidation and in the elimination 
of free radicals (Jiang 2014, Traber 2007). Nevertheless, 
in presence of transition metals (Schoenfeld et al. 2017) 
or under decreased levels of glutathione (Nauser et al. 
2015), ascorbic acid can behave as an oxidative mole‑
cule, increasing the production of oxygen free radicals. 
This property has been recently explored to kill cancer 
cells (Schoenfeld et al. 2017).
Ascorbic acts as a cofactor for several enzymes 
(Lane and Richardson 2014). Scurvy has been associ‑
ated to psychiatric symptoms (Carr and Vissers 2012, 
DeSantis 1993, Kinsman and Hood 1971), and several 
preclinical and clinical studies indicate ascorbic acid 
has effects on cognition and emotion, which seem to 
be unrelated to its classical role as a vitamin. Of note, 
ascorbic acid modulates glutamatergic function (Ma‑
jewska et al. 1990, Moretti, et al. 2012b), and exhibits 
antidepressant activity in different rodent models of 
depression (Moretti, et al. 2012a, 2012b, 2015) through 
a mechanism dependent on mTOR activation, similar to 
ketamine (Moretti et al. 2014). There is scarce informa‑
tion in the literature regarding a potential anxiolytic 
effect of ascorbic acid. A few studies on non‑clinical 
samples have shown that ascorbic acid can produce im‑
provement in mood and relieve on depressive and anx‑
iety symptoms (Brody 2002, Khajehnasiri et al. 2013, 
de Oliveira et al. 2015). Ascorbic acid can be effective 
in patients with major depression, generalized anxiety 
disorder and general medical conditions (Amr et al. 
2013, Gautam et al. 2012, Mazloom et al. 2013, Zhang 
et al. 2011). These studies have focused on the effects 
of ascorbic acid administered over a period of weeks 
to months while the short‑term effects of a single dose 
of ascorbic acid on emotional states are unknown.
The exact mechanisms associated with the puta‑
tive anxiolytic effects of ascorbic acid are unknown. 
Preclinical studies include a series of possible tar‑
gets, such as antioxidant and neuroprotective action 
(Moretti et al. 2012a, 2012b), and mechanisms related 
to the antidepressant action of ascorbic acid (Binfaré 
et al. 2009, Lopresti 2015, Majewska et al. 1990, Moretti 
et al. 2012a, 2012b, 2014, 2015, Yusa 2001), which can 
potentially be explored to treat anxiety. The signaling 
pathways that could be implicated in the antidepres‑
sant effect of ascorbic acid effects include activation of 
phosphoinositide 3‑kinase/mammalian target of rapa‑
mycin pathway (Moretti et al. 2014). These modulatory 
pathways include potassium channels (Moretti et al. 
2012a), NMDA receptors, activation of monoaminergic 
systems (Binfaré et al. 2009), as well as pathways in‑
volving nitric oxide (Majewska et al. 1990, Yusa 2001, 
Zomkowski et al. 2012). Interestingly, NMDA adminis‑
tration to mice completely reversed the antidepres‑
sant‑like effect of ascorbic acid, while the combined 
administration of ascorbic acid and a sub‑effective 
dose of MK‑801, an NMDA receptor antagonist, pre‑
sented synergistic antidepressant‑like effect in mice 
(Moretti et al. 2012b). 
In this context, the present study aimed at inves‑
tigating the effects of ascorbic acid on anxiety state 
and mood in a sample of graduate students through 
a double‑blind, randomized, placebo‑controlled design. 
Self‑report measures of anxiety and affect were applied 
before and after the oral administration of a single dose 
of ascorbic acid or placebo. In addition, taking into ac‑
count the possibility that ascorbic acid may elicit an 
anxiolytic effect particularly in anxious subjects; a sec‑
ondary analysis was performed subdividing the sample 
into two groups according to the anxiety background, 
as evaluated by State‑Trait Anxiety Inventory (STAI) 
Trait score.
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METHODS
Participants
The Human Research Ethics Committee of the Fed‑
eral University of Santa Catarina approved the protocol 
(number 1147315), and the investigation was carried 
out in accordance with the latest version of the Dec‑
laration of Helsinki. Informed consent of participants 
was obtained after procedures had been fully explained 
A sociodemographic questionnaire, including questions 
about the current use of psychotropic medications was 
also presented to participants. Participants were grad‑
uate students of both genders but mostly constituted 
of women (>95%), recruited in lato sensu post‑gradua‑
tion courses in the cities of Florianópolis and São Pau‑
lo, Brazil. Subjects who reported allergy related to the 
use of ascorbic acid preparations, pregnancy, history of 
acute of chronic renal failure, or regular supplementa‑
tion with ascorbic acid were not included in the study. 
Regular diet and physical activity, and psychiatric di‑
agnosis, were not controlled. Some individuals (5–8%) 
did not fill the post‑treatment forms, 8 individuals for 
the STAI and 10 for the VAMS, thus were excluded from 
the analysis. Missing values are detailed in the legend 
to Table I. From 144, six individuals in the control and 
two in the ascorbic acid group reported psychotropic 
use, and 27% in each group reported chronic diseases.
Psychological measures
Anxiety and affect were assessed by the self‑report 
measures STAI (Spielberger et al. 1970) and VAMS (Nor‑
ris 1971). Both questionnaires were adapted and validat‑
ed in Brazil (Biaggio et al. 1977, Gorenstein and Andrade 
1996, Zuardi et al. 1993, Zuardi and Karniol 1981). The 
STAI is comprised by the anxiety state (S‑anxiety) and 
the anxiety trait (T‑anxiety) scales, each one including 
20 items with 4 Likert responses; score ranges from 20 
to 80; the higher the scores the higher the anxiety trait 
or state. The VAMS is an analog scale comprised by 16 
pairs of adjectives of opposite feelings separated by 
a 100 mm line; the respondent is instructed do mark the 
line according to how he or she feels at the time of as‑
sessment. The adjectives represent extreme feelings and 
can be generally regarded as “positive” or “negative” 
(e. g. strong‑feeble, happy‑sad, contented‑discontented, 
interested‑bored). A mean overall score can be calculat‑
ed – the higher the measure the higher the “negative” 
feelings – as well as dimensions of anxiety, physical se‑
dation, mental sedation, and other feelings.
Depressive and anxious symptoms were evaluated 
using the Brazilian version of the Hospital Anxiety and 
Depression Scales (HADS) (Botega et al. 1998, Zigmond 
and Snaith 1983). The HADS is comprised by the anxiety 
subscale and the depression subscale, each one with 14 
items with 4 responses; scores in subscales range from 
0 to 21.
Procedures
The study has a double‑blind, randomized, pla‑
cebo‑controlled design. Participants were informed 
about the objective of this work and were aware about 
the existence of ascorbic acid or vehicle in capsules 
and that researchers did not have access to this infor‑
mation. Participants were asked to avoid drinking tea, 
coffee or other stimulating substances before testing. 
As vitamin C has a sour taste, participants were in‑
structed to avoid chewing the capsules, thus remaining 
blind regarding the experimental group they belong to. 
Authors are unware if any participant did not respect 
this instruction, and this is a limitation of our work. 
The known side effects of ascorbic acid was explained 
in the consent form. While participants were attend‑
ing their weekend post‑graduation classes, trials were 
performed in the morning in the student’s classroom 
during a class interval and participants were instructed 
not to intake any food, drink or dietary supplements 
during a two‑hour period, and not have ingested ascor‑
bic acid for at least six hours before the test. Around 
10: 00 a.m., and immediately before the administration 
of ascorbic acid or placebo, participants answered the 
VAMS, STAI S‑anxiety and T‑anxiety scales, and HADS. 
Thereafter, students in a given row received two gelatin 
capsules containing 500 mg ascorbic acid each (Hebel 
Welcome, China), and the students in the next row re‑
ceived two gelatin capsules containing cornstarch. Wa‑
ter in a disposable cup was provided along the capsules. 
The procedure was repeated for the next two rows, and 
so on, in a way that groups were balanced in size for the 
two groups, ascorbic acid and placebo. Starting row and 
starting groups were alternated each other class. After 
two hours, students answered VAMS and STAI S‑anxiety 
scale. Capsules were identified by a numerical code and 
researchers who administered them were blind to their 
content, and groups were only disclosed after compila‑
tion and analysis of all data.
Data analyses
Changes from baseline emotional states were de‑
fined by differences between the scores in the VAMS 
and S‑anxiety scale. For each of these scales and the 
factor subscales of VAMS, the score after treatment mi‑
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nus the score before treatment was computed. Further 
analyses were carried comparing placebo and ascorbic 
acid groups according to a cut‑off score of 75% in the 
STAI T‑anxiety scale: individuals scoring in the 75% 
lower percentile were defined as “low‑to‑moderate 
trait anxiety”, while individuals presenting the 25% 
highest scores were denominated as “high trait anxi‑
ety” (Table I). “Low‑to‑moderate trait anxiety” placebo 
group was composed of 95% females, while the ascor‑
bic acid was 98%. Placebo group presented 5.4% and 
ascorbic acid 2% of individuals reporting psychotropic 
use, while chronic diseases rated 25.5% and 27.5%, re‑
spectively, among the “low‑to‑moderate trait anxiety”. 
In the “high trait anxiety” group, 100% were female, 
three individuals in placebo and one in the ascorbic 
acid group reported psychotropic use, while chronic 
diseases amounted to 35.7% in placebo and 26.1% in 
the ascorbic acid group. No differences were found be‑
tween placebo and ascorbic acid regarding gender, psy‑
chotropic use, and chronic diseases.
By repeating statistical analysis in subgroups 
(low‑to‑moderate trait anxiety and high trait anxiety), 
these additional comparisons using the same sample 
increases the chances of false positive results. Alike, 
comparison of subscales in the VAMS questionnaire re‑
sults in testing a family of closely related hypotheses. 
These are possible weaknesses of our work, needing to 
be taken in account when interpreting results.
Continuous variables were compared using the un‑
paired t‑test or Mann‑Whitney U test according to the 
normality of data, as defined by the Kolmogorov‑Smirn‑
ov test. Categorical variables were analyzed using Fish‑
er exact test. A significance level of p less than 0.05 was 
set for all statistical tests. Data was analyzed using the 
SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA) and 
graphics were plotted using GraphPad Prism 6 for Win‑
dows (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
The demographic and baseline characteristics of 
participants are summarized in Table I, while Table II 
present average values and standard deviation after in‑
gestion of placebo or ascorbic acid. In addition to the 
treatment groups, sample was secondarily ranked as 
“low‑to‑moderate”, and “high trait anxiety”, as defined 
by a STAI T‑anxiety scale score higher than or equal to 
50 (corresponding to 25% of the sample). Basal levels 
are presented in Table I, while Table II present values 
2 hours after placebo or ascorbic acid ingestion. Place‑
bo and ascorbic acid groups did not differ at baseline 
in terms of: gender, self‑reported use of psychotropic 
medications (antidepressants and benzodiazepines, 
other psychotropic medications were not reported), 
and scores in the HADS anxiety and depression sub‑
scales, T‑anxiety and S‑anxiety scales, and VAMS and 
its factor subscales. Subjects spontaneously reported 
no adverse effects attributable to ascorbic acid. Sub‑
jects within the low‑to‑moderate trait anxiety group, 
Table II. Visual Analogue Mood Scale (VAMS) and State‑Trait Anxiety Inventory (STAI) State anxiety scores of the sample, grouped as low‑to‑moderate trait 
anxiety or as high trait anxiety, according to STAI Trait anxiety score after placebo or ascorbic acid ingestion. High trait anxiety was defined as the group 
presenting Trait‑STAI scores equal or higher than the 75th percentile of the sample, while the remaining of the sample was included in the low‑to‑moderate 
trait anxiety group
Variablesa, b
All subjects (n=144) Low‑to‑moderate trait anxiety subjects (n=107) High trait anxiety subjects (n=37)
Placebo n Ascorbic acid n Placebo n
Ascorbic 
acid n Placebo n
Ascorbic 
acid n
VAMS (mm)
 Score 590.0±223.1 56 602.0±243.9 62 569.9±198.3 46 563.1±240.8 43 682.4±309.7 10 689.9±233.5 19
 Anxiety  127.9±60.6 56 123.0±63.1 62 120.2±58.7 46 112.0±58.7 43 163.2±59.6 10 147.7±67.5 19
  Physical 
sedation 254.5±109.9 56 271.0±125.9 62 244.0±98.4 46 250.5±121.4 43 302.7±149.0 10 317.5±126.7 19
 Mental sedation 84.6±41.4 56 91.2±48.8 62 84.2±38.3 46 91.7±49.8 43 86.7±56.1 10 90.2±47.6 19
 Other feeling 122.9±67.3 56 116.7±62.6 62 121.4±60.9 46 108.9±58.6 43 129.8±95.5 10 134.5±69.2 19
STAI
  State anxiety 
score 40.3±8.3 62 41.3±9.8 65 38.6±7.1 49 37.1±6.6 45 46.8±9.5 13 50.7±9.3 20
a All variables had a normal distribution according to the Kolmogorov‑Smirnov test and are shown as mean ± SD. b Data missing for the following variables: VAMS, 26; STAI state 
anxiety, 17.
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who received ascorbic acid, were older than those who 
received placebo, with a mean ± standard deviation of 
the mean (SD) of 28.6±6.1 and 30.0±6.3 years (p=0.03).
Fig. 1 depicts changes from baseline in the STAI 
S‑anxiety scale: scores taken two hours after treatment 
minus scores immediately before treatment. There was 
no change from the baseline value difference (mean±SD, 
n) between placebo (‑0.0±6.3, 62), and ascorbic acid 
(‑1.7±9.3, 65), p=0.24 (Fig. 1A). Analysis of subjects with 
low‑to‑moderate trait anxiety also revealed no differ‑
ences between placebo (‑0.2±6.2, 49), and ascorbic acid 
(0.5±7.5, 45) groups, p=0.60 (Fig. 1B). However in sub‑
jects with high trait anxiety, the scores in the ascorbic 
acid group was significantly lower (‑6.6±11.2, 20) than 
placebo group (0.85±7.0, 13), p=0.04 (Fig. 1C).
Fig. 2 shows the VAMS analyses and its factor subscales: 
anxiety, physical sedation, mental sedation, and other 
feelings. When changes from baseline were analyzed, tak‑
ing into account the scores in millimeters, two hours after 
treatment minus scores immediately before treatment, 
(Fig.  2A),  no  differences  were  observed  between  place‑
bo and ascorbic acid group (mean ± SD, n). VAMS: pla‑
cebo 24.0±220.9, 56, ascorbic acid ‑46.7±253.7, 62, p=0.61; 
and subscales Anxiety: placebo ‑5.9±58.2, ascorbic acid 
21.0±68.5, p=0.20; Physical sedation: placebo ‑6.1±105.2, 
ascorbic acid ‑14.8±130.3, p=0.69; Mental sedation: placebo 
‑14.9±55.8, ascorbic acid ‑11.3±56.3, p=0.71; Other feelings: 
placebo 2.9±52.7; ascorbic acid 0.01±65.8, p=0.79. 
Analysis of subjects with low‑to‑moderate trait anx‑
iety (Fig. 2B) also revealed no change in the baseline 
VAMS score (mean±SD, n) between placebo (‑21.5±208.0, 
46), and ascorbic acid (18.4±235.8, 43) groups p=0.40. The 
same was observed in the VAMS subscales: Anxiety: pla‑
cebo ‑6.4±59.0; ascorbic acid ‑3.3±60.5, p=0.81; Physical 
sedation: placebo ‑4.8±99.3; ascorbic acid 13.4±113.4, 
p=0.42; Mental sedation: placebo ‑15.6±56.0, ascorbic 
acid ‑1.3±50.1, p=0.21. Other feelings: placebo 5.2±46.1, 
ascorbic acid 9.2±67.6, p=0.74. 
Interestingly, subjects in the ascorbic acid group, 
in the sub‑set sample with high trait anxiety (Fig. 2C), 
presented significantly lower VAMS score in the anxi‑
ety factor subscale (mean±SD, n): placebo ‑3.8±57.6, 10, 
ascorbic acid ‑61.0±70.1, 19, p=0.04 (Fig. 2C). The VAMS 
overall score and the scores in other factor subscales 
did not differ between placebo and ascorbic acid group. 
VAMS: placebo ‑35.3±285.9, ascorbic acid ‑193.5±235.9, 
p=0.12; Physical sedation: placebo ‑12.3±135.2, ascor‑
bic acid ‑78.6±146.0, p=0.24; Mental sedation: placebo 
‑11.9±57.5, ascorbic acid ‑33.2±64.5, p=0.39; Other feel‑
ings: placebo ‑7.3±79.0, ascorbic acid ‑20.8±57.8, p=0.60.
Fig. 1. Effects of ascorbic acid on anxiety state evaluated by the State‑Trait Anxiety Inventory (STAI). Immediately before the oral administration of placebo 
or 1000 mg of ascorbic acid STAI state‑anxiety scale was applied, and was reapplied two hours later. Changes from baseline scores are shown as mean 
and standard error of the mean. Low‑to‑moderate and high trait anxiety subjects were defined by a score in the STAI trait‑anxiety scale applied at baseline 
lower or higher than or equal to the 75th percentile of the sample. Analyses of all subjects (n=62 and 65 for placebo and ascorbic acid groups, respectively) 
and subjects with low‑to‑moderate trait anxiety (n=49 and 45 for placebo and ascorbic acid groups, respectively) revealed no differences between the 
groups (p > 0.05). Analyses of subjects with high trait anxiety (n=13 and 20 for placebo and ascorbic acid groups, respectively) showed greater reduction 
of STAI state‑anxiety scores in the ascorbic acid group (*p=0.04), as evaluated by unpaired t‑test.
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DISCUSSION
The present study employed a double‑blind, ran‑
domized, placebo‑controlled design to evaluate the 
effects of a single oral dose of ascorbic acid (1000 mg) 
over anxiety and other emotional states, as measured 
by STAI and VAMS, in a non‑clinical sample of young 
graduate students. STAI and WAMS were applied 
two hours after the ingestion of ascorbic acid, a time 
point ascorbic acid reaches maximal concentration 
in human plasma after oral administration (Carr et 
al. 2013), the anxiety scores remained at basal levels 
(pre‑treatment levels). However, a secondary analysis 
suggested the effects of ascorbic acid were dependent 
on trait anxiety (defined as low‑to‑moderate or high 
by a cut‑off at the 75th percentile of the sample in the 
STAI T‑anxiety scale). As compared to baseline, ascor‑
bic acid produced a significant anxiolytic effect, which 
was restricted to subjects with high trait anxiety, as ev‑
idenced by a significant decrease in the STAI S‑anxiety 
scale, and in the VAMS anxiety subscale scores. 
Overall, placebo and ascorbic acid groups present‑
ed similar sociodemographic characteristics, and base‑
line trait and state anxiety and other emotional states, 
and depressive and anxious symptoms, ruling out the 
possibility that the observed effects are attributable to 
pre‑treatment differences in these variables. Subjects 
with low‑to‑moderate trait anxiety receiving placebo 
were younger than those who received ascorbic acid, 
but a median difference of about two years in young 
adults seems unlikely to lead to differences in metabo‑
lism of ascorbic acid and cognition.
A limitation of the present study is the use of a sam‑
ple with specific sociodemographic characteristics, 
composed primarily of young female university stu‑
dents undertaking post‑graduation courses. This may 
reduce the external validity of our findings to other 
populations, especially males. Gender differences have 
been described in manifestations of trait and state anx‑
iety (McLean and Anderson 2009), as well as in ascor‑
bic acid metabolism (Blanchard 1991, Oreopoulos et al. 
1993). Another limitation is the relatively small sam‑
ple size in the secondary analysis of subjects with high 
trait anxiety. Therefore, replication in larger samples 
may be necessary to confirm, or not, our findings. In 
addition, variables such as regular diet and physical ac‑
tivity, and psychiatric diagnosis, were not controlled. 
However, the absence of differences in depressive and 
anxious symptoms in HADS, as well as the low rate of 
self‑reported use of psychotropic medication, mini‑
mize these issues. The known anti‑inflammatory ef‑
fects of ascorbic acid (Sorice et al. 2014) can be a con‑
founding variable in decreasing scores in STAI scale, 
however ascorbic acid supplementation may not alter 
Fig. 2. Effects of ascorbic acid on anxiety state by the Visual Analog Mood Scale 
(VAMS). Immediately before the oral administration of placebo or 1000 mg of 
ascorbic acid VAMS was applied, and was reapplied two hours later. Changes 
from baseline scores are shown as mean and standard error of the mean. 
Low‑to‑moderate and high trait anxiety subjects were defined by a score in the 
STAI trait‑anxiety scale applied at baseline lower or higher than or equal to the 
75th percentile of the sample. Analysis were performed using the overall score of 
the VAMS and scores in the factor subscales anxiety, physical sedation, mental 
sedation and other feelings. Analyses of all subjects (n=56 and 62 for placebo 
and ascorbic acid groups, respectively) and subjects with low‑to‑moderate 
trait anxiety (n=46 and 43 for placebo and ascorbic acid groups, respectively) 
revealed no differences between groups (p > 0.05). Analyses of subjects 
with high trait anxiety (n=10 and 19 for placebo and ascorbic acid groups, 
respectively) showed greater reduction in the anxiety factor scores in the 
ascorbic acid group (*p=0.04), as evaluated by unpaired t‑test.
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basal levels of inflammatory cytokines (Ellulu et al. 
2015, Veskoukis et al. 2016). Despite these limitations, 
to our knowledge, this is the first report showing the 
ability of a single dose of ascorbic acid to elicit anxi‑
olytic effects in humans. Future research on ascorbic 
acid would benefit from physiological measures of 
stress such as hemodynamic parameters, cortisol and 
oxidative stress.
STAI and WAMS were applied two hours after the 
ingestion of ascorbic acid, a time point ascorbic acid 
reached maximal concentration in human plasma after 
an oral administration (Carr et al. 2013). Daily supple‑
mentation with 500 or 1000 mg ascorbic acid maintain 
elevated plasma ascorbic acid levels for several hours 
(Mason et al. 2014, de Oliveira et al. 2015), which is 
a desired characteristic of a therapeutic drug.
Interestingly, our results are in line with the limit‑
ed available data on humans. In a recent double‑blind, 
randomized, placebo‑controlled study (de Oliveira et 
al. 2015), lower levels of anxiety were found as mea‑
sured by the Beck Anxiety Inventory, after oral supple‑
mentation with ascorbic acid 500 mg, daily for 14 days, 
in a non‑clinical sample of high school students. A ran‑
domized single blind placebo‑controlled trial also found 
decreased anxiety scores in the Depression Anxiety 
Stress Scale‑21 in adults with type 2 diabetes, after oral 
supplementation with ascorbic acid (1000 mg daily for 
six weeks) (Mazloom et al. 2013). Animal studies also 
support the idea of an anxiolytic effect of ascorbic acid. 
Zebrafish exposed to methylmercury presented anxi‑
ety‑like behavior, which was abolished by a pre‑treat‑
ment with ascorbic acid (Puty et al. 2014). In another 
study (Hughes et al. 2011), anxiety‑like behavior was 
decreased in rats fed with ascorbic acid for 3 months.
In our study ascorbic acid had effects only in sub‑
jects with high trait anxiety. Trait anxiety can be broad‑
ly defined as a predisposition to experience anxiety as 
a response to stress and psychological threats (Endler 
and Kocovski 2001, Reiss 1997).
The specific neurobiology of a given psychiatric dis‑
order can be related to different patterns of outcomes. 
The idea of defining more homogeneous subgroups of 
patients, potentially able to respond differently to treat‑
ments, is one of the aims of the Research Domain Crite‑
ria (RDoC) initiative of the National Institute of Mental 
Health (Insel 2014). RDoC seeks to integrate neurosci‑
ence and psychiatry at research level through a classi‑
fication with a strong biological validity (Cuthbert and 
Insel 2013). Although trait anxiety is a psychological 
concept and not a neurobiological marker, it has been al‑
ready shown to affect cognitive and social responses and 
to be linked to the activation of brain circuits involving 
mainly the amygdala and prefrontal cortex (Bishop 2009, 
Etkin et al. 2004, Xu et al. 2013). In fact, the STAI is list‑
ed in the RDoC matrix as a self‑report measure of the 
construct acute threat/fear in the domain of negative 
valence systems. Since RDoC is strongly translational, it 
reflects the classical ethological differentiation between 
fear and anxiety (Tovote et al. 2015). The role of this dif‑
ferentiation remains to be understood at clinical level 
(Perusini and Fanselow 2015).
 As previously mentioned, anxiety and depres‑
sive symptoms are frequently concomitant. They also 
seem to share several common neurobiological mech‑
anisms (Goodwin 2015, Kessler et al. 2003). Studies in 
humans have shown that ascorbic acid also has anti‑
depressant effects. In a double‑blind, randomized, pla‑
cebo‑controlled trial (Brody 2002), a high dose of oral 
ascorbic acid (3000 mg), when administered for 14 days 
to healthy young adults, decreased scores in the Beck 
Depression Inventory, and increased sexual inter‑
course frequency. A double‑blind, randomized, place‑
bo‑controlled study showed that the administration of 
1000 mg of oral ascorbic acid for six months, adjunctive 
to fluoxetine in a pediatric sample, produced an addi‑
tional decrease on depressive symptoms as compared 
to fluoxetine alone (Amr et al. 2013), suggesting that 
ascorbic acid may be useful for depressive pediatric pa‑
tients (Lopresti 2015). Other studies have shown simi‑
lar results in humans (Gautam et al. 2012, Khajehnasiri 
et al. 2013, Zhang et al. 2011). Our group has demon‑
strated antidepressant effects of ascorbic acid in mice 
subjected to tail suspension test (Binfaré et al. 2009), 
acute restraint stress (Moretti et al. 2013), chronic un‑
predictable stress, and on the depressive‑like behavior 
induced by administration of the pro‑inflammatory 
cytokine tumor necrosis‑alpha (Moretti et al. 2012a, 
2012b, 2015).
It is remarkable that pregabalin has been pointed 
as a first line choice for the treatment of generalized 
anxiety disorders (Baldwin et al. 2015, Martinotti et al. 
2013). Interestingly, pregabalin present a rapid anxio‑
lytic effect (Nutt et al. 2009), similar to the effect pre‑
sented in this work. While pregabalin can decrease the 
release of glutamate (Martinotti et al. 2013), ascorbic 
acid can impair the glutamate binding to the NMDA re‑
ceptor (Majewska et al. 1990). Furthermore, pregabalin 
can activate glutamate transport, clearing glutamate 
(Ryu et al. 2012), possibly increasing ascorbic acid re‑
lease, as proposed earlier by the action of anionic high 
affinity glutamate transporters (EAAT2 e EAAT3) (Re‑
bec and Pierce 1994). Based on these data, it is tempting 
to speculate that the anxiolytic effect of ascorbic acid 
can be related to a negative modulation of glutamater‑
gic neurotransmission.
This work presents the first evidence for a rapid anx‑
iolytic effect of ascorbic acid in a sub‑sample of high 
trait anxiety individuals. The present results combined 
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with previous evidence suggesting that ascorbic acid 
may play a significant role in mood regulation, and the 
fact that its use as a nutritional supplement is safe and 
inexpensive (Verhamme et al. 2009), warrant further 
clinical studies dealing with its potential as an anxio‑
lytic agent. Future mechanistic studies are necessary to 
provide clues for the development of new treatments. If 
confirmed, the use of ascorbic acid may be considered 
for the clinical practice, either as a supplement for nor‑
mal individuals presenting high trait anxiety, or as an 
adjuvant for the treatment of anxiety disorders.
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